Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.Â
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.Â
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.Â
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.Â
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
